Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALOX12
REST API REST API
Homo sapiens
ALOX12 is differentially expressed in 158 experiments: 60 organism parts: tongue, esophagus, ... (58 more);, 115 disease states: normal, lung adenocarcinoma, ... (113 more);, 43 cell types 82 cell lines 14 compound treatments and 63 other conditions.
Synonyms 12S-LOX
Orthologs Alox12 (Mus musculus)   F1MFA8_BOVIN (Bos taurus)   Alox12 (Rattus norvegicus)   ALOX12 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, oxidoreductase activity, positive regulation of caspase activity, leukotriene biosynthetic process, protein binding, iron ion binding, cytoplasm, cellular component movement, positive regulation of cell proliferation, positive regulation of gene expression, negative regulation of apoptosis, metal ion binding, anti-apoptosis, positive regulation of apoptosis, sarcolemma, fatty acid oxidation, oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen, positive regulation of cell growth, superoxide anion generation, positive regulation of cell adhesion, positive regulation of cell killing, lipoxygenase activity, positive regulation of endothelial cell migration, arachidonate 12-lipoxygenase activity, positive regulation of mitochondrial depolarization, negative regulation of cell killing, hepoxilin-epoxide hydrolase activity, positive regulation of endothelial cell differentiation, oxidation-reduction process, reactive oxygen species metabolic process
InterPro Term LipOase_LH2, LipOase_C, LipOase_mml
UniProt Accession P18054
Search EB-eye ENSG00000108839
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, E-GEOD-24147, ... (16 experiments)

Factor Value U/D Experiments
MDA468
1
E-MEXP-440
DU145
1
E-GEOD-17482
OE21
1
E-MTAB-37
NA18853
1
E-GEOD-19480
SJSA1
1
E-MTAB-37
COLO201
1
E-MTAB-37
76 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, E-GEOD-11755, E-GEOD-21909, ... (29 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-18147, E-GEOD-18265
whole blood
1
E-GEOD-3026
pro B cell
1
E-MEXP-1403
hematopoietic progenitor cells
1
E-MEXP-70
Embryonic Kidney cell
1
E-GEOD-20677
keratinocyte
1
E-GEOD-3204
37 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-5563, E-GEOD-2549, E-GEOD-20602, E-MEXP-66, ... (29 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-20602, E-GEOD-20295
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
esophageal adenocarcinoma
1
E-GEOD-1420
myeloid leukemia
1
E-MTAB-37
109 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-412, E-GEOD-7216, E-GEOD-2803, E-GEOD-5824, ... (10 experiments)

Factor Value U/D Experiments
vanadium pentoxide
1
E-GEOD-5339
1,2,4-benzenetriol
1
E-GEOD-7664
control
30
1
E-GEOD-7664
granulocyte-colony stimulating factor
1
E-GEOD-7400
MIG control
1
E-GEOD-15811
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
8 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
42
1
1
E-GEOD-21653
36
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-1561, E-TABM-147, E-GEOD-21138

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genotype
studied in E-MEXP-421, E-GEOD-22593, E-TABM-321, E-TABM-868, E-MEXP-1403 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-1446, E-GEOD-10315

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-TABM-666, ... (22 experiments)

Infection
studied in E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-1657, E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-MEXP-973, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.519 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM